INTRODUCTION
============

A critical care physician often has to manage patients who either present with or develop coagulation abnormalities in intensive care unit, and they are a predictor of both, the need for massive transfusion and mortality.^[@B1]^ These abnormalities can range from something as simple as isolated thrombocytopenia to more complex multisystem coagulation defects. [Table 1](#T1){ref-type="table"} shows the common causes of coagulopathy in critically ill patients. Moreover, in critically ill patients, assessing bleeding risk is one of the key management strategies to minimize any procedural or perioperative bleeding. Critically ill patients can be prone to bleeding for a wide variety of reasons including hereditary or acquired bleeding disorders (platelet function abnormalities, factor deficiencies and factor inhibitors), underlying medical conditions such as hepatic or renal disease and concomitant anticoagulation medications. Besides, certain connective tissue disorders can impact on the integrity of blood vessels, which make them more prone to bruising/bleeding.

UNDERSTANDING NORMAL HEMOSTASIS
===============================

Hemostasis is a complex process and involves multiple steps ([Fig. 1](#F1){ref-type="fig"}). It is subdivided into four phases. The first phase of primary hemostasis involves vasoconstriction and platelet plug formation and is triggered when the subendothelial collagen is exposed after vessel wall injury. This leads to platelet adhesion to the subendothelial layer via von Willebrand and glycoprotein Ib and subsequent platelet aggregation. Next comes secondary hemostasis, which involves the activation of coagulation factors and thrombin formation. Phase 3 requires fibrin clot formation and stabilization, and the final step requires inhibition of thrombin generation and fibrinolysis. Traditionally, this process has thought to occur via three pathways. The intrinsic pathway (uses factors VIII, IX, XI, XII), extrinsic pathway (uses factor VII), and common pathway where both converge to activate factor X (uses factors II, V, fibrinogen). In the new proposed coagulation cascade, this complete process does not occur continuously but instead requires three consecutive phases: namely, an initial phase, an amplification phase and the propagation phase.

###### 

Common causes of coagulopathy in critically ill

  *Secondary disruption of hemostasis*                                                                                                                                                                               *Deranged hemostasis*                                                                                                                                                                          *Hyperfibrinolysis*^[@B2]^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------
  Hypothermia (Temp \<34^o^C)Severe acidosis (pH \<7.25)Hypocalcemia (iCa^++^ \<1 mmol/L)                                                                                                                            ***Consumption***                                                                                                                                                                              ***Acquired secondary***
  SepsisDICCardiac surgery                                                                                                                                                                                           SepsisDICExtracorporeal circuits (CRRT),Enlarged spleen                                                                                                                                        TraumaThrombolytic therapyCardiopulmonary bypassSystemic amyloidosisPlacental disorders
  *Blood Loss*                                                                                                                                                                                                       *Acquired Primary*                                                                                                                                                                             
  Multiple trauma and major blood loss                                                                                                                                                                               Multiple trauma and major blood loss                                                                                                                                                           End-stage liver cirrhosisAcute promyelocytic leukaemia
  *Decreased generation/Drugs*                                                                                                                                                                                       *Inherited secondary*                                                                                                                                                                          
  Vitamin K deficiencyVitamin K antagonistsLiver disease and renal failureHemophiliaFXIII deficiencyDysfibrinogenemiasDrugs: Heparin, novel oral anticoagulants, direct thrombin inhibitors, direct Xa inhibitors.   Bone marrow suppressionVitamin B~12~ and folate deficiencyMyelosuppressionDrugs: Acetaminophen, carbamazepine, hydrochlorothiazide, cimetidine, ranitidine, quinidine, quinine, bactrim, etc   HemophiliaFXIII deficiencyDysfibrinogenemias

![Simplified diagram of Hemostasis](ijccm-23-s215-g001){#F1}

###### 

Screening and confirmatory test for hemostasis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                      *Screening test*                                                                      *Confirmatory test*
  ------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------
  Coagulation         aPTT, PT, Thrombin time (TT)                                                          FII, V, VII, VII, IX, X, XI, XII, XII activity\
                                                                                                            Fibrinogen activity

  vWF                 Platelet function analyzer, vWF antigen                                               Antigen and platelet activity, genetic testing, propeptide testing

  Platelet function   Platelet countBleeding time (BT)Platelet function analyzer                            Light transmission aggregometry with arachidonic acid, thrombin receptor-activating peptide, collagen, adenosine diphosphate

  Fibrinolysis        Euglobulin lysis time                                                                 tPA, plasminogen activity inhibitor, alpha-2 antiplasmin

  Anticoagulation     aPTT, PT, TT, BT, anti-FXa activity, thrombin inhibition time (TTI), reptilase time   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The liver is responsible for the production of most of the factors, namely; I, II, V, VII, VII, IX, X, XI, XIII and protein C (FXIV) and protein S. Thus, patients with advanced liver disease often have coagulopathy. The coagulation system also has a negative feedback mechanism to prevent overcoagulation and thrombosis. Thrombin also acts by activating plasminogen (to plasmin, which is an active enzyme in fibrinolysis) and stimulating the production of antithrombin (which decreases the production of thrombin and decreases the output of FXa).

EVALUATING COAGULATION
======================

The most obvious indications that a patient has coagulopathy are an unusual drop in hemoglobin or persistent bleeding. This often manifests as the presence of ecchymosis, petechiae, haematuria, hematomas or prolonged bleeding from puncture sites. Excessive bleeding from surgical drains or incision sites may also occur. If the bleeding is significant and allowed to continue, it may lead to hypovolemic shock, hypoperfusion and organ failure. Apart from above physical signs of bleeding, one should also look for jaundice, splenomegaly, arthropathy, joint and skin laxity (Marfans or Ehlers-Danlos syndrome) as signs of systemic or connective tissue disorder. The other causes of easy bruising like alcohol abuse, purpura simplex, Cushing\'s disease, vitamin C deficiency should also be screened for. One should also take a detailed medication history to check if the patient is taking medications such as antiplatelet agents, anticoagulants (warfarin or NOVACs) and complementary medications that affect coagulation. Drugs like cephalosporins, ginkgo-biloba, interferon, SSRI, TCA are rare causes that can cause bleeding and bruising.^[@B3]^

The screening tests for hemostasis are summarized in [Table 2](#T2){ref-type="table"}. Despite their limitations, both prothrombin time (PT) and activated partial thromboplastin time (aPTT) remain the most common screening test to evaluate coagulation. PT measures the integrity of extrinsic and common pathway while aPTT measures the integrity of the intrinsic and common pathway. They assess the time it takes for both the pathways to generate cellular plasma and thus only investigate a narrow part of the coagulation system. [Figure 2](#F2){ref-type="fig"} highlights the factors involved in each pathway. These tests are designed for clinical monitoring of anticoagulation and not coagulopathy and thus only serve as useful starting points of investigation of coagulation. Mixing studies are done to determine whether a prolonged PT or aPTT or both are affected by the presence of a factor deficiency or a factor inhibitor. If the test normalises when plasma is added, it is due to factor deficiency, and if not, it is secondary to the presence of an inhibitor like lupus anticoagulant.

![Factors involved in the extrinsic (yellow), intrinsic (blue) and common pathways (red)](ijccm-23-s215-g002){#F2}

###### 

Initial assessment of prolonged PT and aPTT in a patient with bleeding

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *PT*        *aPTT*      *Causes*                                                                                                    
  ----------- ----------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  Normal      Normal      von Willebrand\'s disease\                                                                                  Platelet dysfunction\
                          FXIII deficiency, Dysfibrinogenemia                                                                         α-antiplasmin deficiency

                          Mixing study corrects                                                                                       Mixing study does not correct

  Prolonged   Normal      *Hereditary* Isolated FVII deficiency *Acquired* Vitamin K deficiency/ antagonistsSevere liver impairment   Inhibitors Lupus anticoagulantFVII inhibitor (rare)

  Normal      Prolonged   *Bleeding* FVIII/vWD deficiency, FIX/XI deficiency *No bleeding* FXII, HMWK, prekallikrein                  *Bleeding* FVIII, FIX, FXI inhibitor, heparin *No bleeding* FXII inhibitor, lupus anticoagulant HMWK, prekallikrein

  Prolonged   Prolonged   FII, FV, FX deficiencyFV and FVIII deficiencySevere liver impairmentVitamin K deficiency/antagonistDIC      FII, FV, FX inhibitorLupus anticoagulant
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Assessment of coagulation for patients on anticoagulants

  *Test*     *Anticoagulant*   *Reference range*                                    
  ---------- ----------------- ------------------- ---------------- --------------- ------------
  PT         Normal            Prolonged           Prolonged        Prolonged       \<35 sec
  aPTT       Normal            Prolonged           Normal           Prolonged       \<13.5 sec
  TT         Normal            Prolonged           Normal           Normal          \<21 sec
  BT         Normal            Normal              Normal           Normal          \<21 sec
  Anti-FXa   Detectable        Not detectable      Not detectable   Detectable      \<0.1
  TTI        No inhibition     Inhibition          No inhibition    No inhibition   

TT, thrombin time; BT, bleeding time; TTI, tissue thromboplastin inhibition

These tests should accompany a detailed history, including medication and clinical examination. It is also essential to get the peripheral smear examination as it also helps in looking at the morphology of platelets and also identify systemic illness and other hematological disorders. [Table 3](#T3){ref-type="table"} highlights the causes of abnormality in these tests and [Table 4](#T4){ref-type="table"} highlights the defect associated with the use of anticoagulants.

Evaluation of Preexisting Coagulation Disorder
----------------------------------------------

The British Committee for Standards in hematology and various Anesthesiology Society guidelines for perioperative assessment recommend evaluation of bleeding risk before surgery or invasive procedures for all patients.^[@B4]--[@B6]^ Bleeding assessment tools (BATs) were developed to offer a simple, structured screening tool to improve the diagnostic accuracy of bleeding disorder with symptom severity, minimise investigations, predict the risk of bleeding and inform about the treatment strategies ([Table 5](#T5){ref-type="table"}).

It is easy to diagnose major bleeding disorders like hemophilia and vWD but challenging to diagnose or classify some of the mild bleeding disorders. In a prospective Indian study, Kotru et al. reported that of the 164 patients who presented with slight bleeding, epistaxis was the most common presentation with cutaneous bleeding, the next common site. A family history of bleeding was present in only 11 patients. Only 25% of the patients were confirmed to have a bleeding disorder based on the investigation, and the rest labeled as unclassified bleeding disorder.^[@B7]^

###### 

Commonly used BAT scores to assess bleeding risk in bleeders

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Tool*                                                                                              *Year developed*   *Scores allotted*   *Target condition*   *Time taken*   *Comments*^[@B8],[@B9]^
  --------------------------------------------------------------------------------------------------- ------------------ ------------------- -------------------- -------------- -------------------------
  Vincenza bleeding score                                                                             2005               0 to +3             Type 1 vWD           40 min         Sensitivity (64%)\
                                                                                                                                                                                 Specificity (99%)

  European molecular and clinical markers for diagnosis and management of type 1 vWD (MCMDM- 1 vWD)   2006               −1 to +4            Type 1 vWD           40 min         Sensitivity (59%)\
                                                                                                                                                                                 Specificity (96%)

  Condensed MCMDM vWD-1                                                                               2008               −1 to +4            Type 2B vWD\         5--10 min      Sensitivity (76%)\
                                                                                                                                             Bleeding disorders                  Specificity (100%)\
                                                                                                                                                                                 Sensitivity (85%)\
                                                                                                                                                                                 Specificity (90%)

  ISTH-BAT                                                                                            2010               0 to +4             Type 1 vWD           20 min         Sensitivity (49%)\
                                                                                                                                                                                 Specificity (47%)

  HEMSTOP                                                                                             2015               0 to 1              Bleeding disorder    5--10 min      Sensitivity (89.5%)\
                                                                                                                                                                                 Specificity (98.6%)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Advantages and disadvantages of blood and pharmacological products

  *Blood Products*                                                                                                                                                                                             *Factor concentrates*                                                                                                                                                                                                                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  *Advantages* FFP contains all factors including vWF and factor XIIIWell studied and included in standardized massive transfusion protocols (MTP)Effective volume therapy in shock patientsRelatively cheap   *Disadvantages* Low concentrationTransfusion related risksRequires cross matchingLarge fluid loadShorter storage lifeThawing takes time and not immediately available   *Advantages* High concentration of factorsFew transfusion related complicationsNo cross match requiredSmall fluid volumes and hence no hemodilution   *Disadvantages* Not all factors availableHigh costsPoint of care testing requiredNeed parallel fluid resuscitation for volume loss

Reversal of Coagulopathy
------------------------

When managing a patient with coagulopathy, it is essential to consult a hematologist. It is also crucial to monitor the response to the treatment given by checking targeted tests. One can correct the factor deficiencies using fresh frozen plasma (FFP) when the coagulopathy is undifferentiated or secondary to causes like severe sepsis and DIC. Factor concentrates are used when one knows the coagulopathy is secondary to specific factor deficiency and or anticoagulant (e.g. warfarin). [Table 6](#T6){ref-type="table"} highlights the advantages and disadvantages of each.^[@B10]^

Plasma transfusion may be useful in a patient who requires volume resuscitation along with multiple factors to correct the coagulopathy (e.g. patients with trauma and or one with massive exsanguination). It is also important to maintain temperature \>35^o^C, ionized calcium levels \>1.1 mmol/L and pH \>7.25 in these patients. One also needs to activate a systematic transfusion therapy with local massive transfusion protocol to improve the delivery of blood products (packed blood cells, fresh frozen plasma, platelets in fixed ratios along with cryoprecipitate if the fibrinogen is \<2.0 g/L). One gram of tranexamic acid followed by an infusion of 1 gram over 8 hours is also used in such scenarios. FFP is effective in correcting high PT as it has a dilution factor secondary to the volume. However, it is uncertain that prophylactically correcting INR decreases the incidence of bleeding. The TOPIC trial, which was an RCT, failed to show that transfusion of FFP (12 mL/kg) to correct the INR (\>1.5--3.0) prevented bleeding complications in patients undergoing central venous catheter placement, percutaneous tracheostomy, chest tube or abscess drainage.^[@B11]^ The amount of FFP needed to increase the desired level of factor concentration also varies. Chowdary et al. found that one may need volume as high as 30 mL/kg to achieve the target.^[@B12]^

###### 

Reference for blood component and factor concentrate administration based on factor deficiency

  *Factor deficient*                             *Blood Component*                                   *Factor concentrates*
  ---------------------------------------------- --------------------------------------------------- ------------------------------------
  FI (fibrinogen)                                Cryoprecipitate (cryo), fresh frozen plasma (FFP)   FI concentrate
  Factor V (labile factor)                       FFP                                                 
  Factor VII (stable factor/proaccelerin)        FFP                                                 Factor VII concentrate
  Factor VIII (antihemophilic factor)            Cryo, FFP                                           Factor VIII concentrate
  von Willebrand\'s disease                      Cryo, FFP                                           Factor VIII concentrate
  Factor IX (Christmas factor)                   FFP                                                 Factor FIX concentrate
  Factor X (Stuart--Prower factor)               FFP                                                 Factor FX concentrate
  Factor XI (plasma thromboplastin antecedent)   FFP                                                 Factor IX complex (II, VII, IX, X)
  Factor XIII (fibrin-stabilizing factor)        FFP                                                 Factor FXIII concentrate

The common risks associated with FFP transfusion are transfusion-related acute lung injury (TRALI), transfusion-related circulatory overload, allergic or anaphylactic reactions. The less frequent complications include risk of transmission of infections, febrile nonhemolytic reactions, hemolytic reactions and red blood cell (RBC) alloimmunization. Factor concentrate therapy ([Table 7](#T7){ref-type="table"}) guided by viscoelastic testing (TEG or ROTEM) has been tried to minimize the use of blood products in patients undergoing major surgery and trauma but the benefits of this approach has not been demonstrated in big multicentre randomized control trials (RCT).^[@B13],[@B14]^

Prothrombin complex concentrate (PCC) has variable concentrates of 4 factors, namely II, VII, IX, and X and are mainly approved for reversal of coagulopathy secondary to vitamin K antagonist. They are also used in the prevention and treatment of bleeding in patients with hemophilia B. Certain PCC also contain small levels of activated FVII. When compared to FFP, PCCs reverse INR faster and are easier to administer as do not need cross-matching. In scenarios when the INR is not corrected post PCC infusion, one should treat the patient with FFP.

Recombinant coagulation products are proteins which are now more readily available for managing bleeding patients on anticoagulants or with specific coagulation deficiencies. These proteins can be modified and can be used in patients with acquired antibodies and inhibitors to various factors. Recombinant activated factor VIIa is approved for patients with hemophilia with inhibitors but increasingly used in patients with life-threatening massive hemorrhage where conventional blood component therapy is unsuccessful. It only works once hypothermia, hypocalcemia, acidosis are corrected, and PT/aPTT optimized. Its significant side-effects are thromboembolic complications. Inactivated-zhzo recombinant FXa (Andexxa) has recently been approved for reversal of the anticoagulation effect of direct FXa inhibitors (apixaban and rivaroxaban). The limitation of this product is that the anticoagulant effect lasts while the infusion is ongoing (2 hours) and its high costs.

Factor XIII plays a vital role in the final step of clot formation and stabilization. Many studies have shown a reduction in factor FXIII in patients put on cardiopulmonary bypass and FXIII replacement, along with antifibrinolytic therapy reduces the risk of postoperative bleeding and in patients with major trauma.^[@B15],[@B16]^ However, the presence alpha-2 antiplasmin protein (which inactivates plasmin) and other clotting factors (VIII, XIII, vWF) in addition to fibrinogen in the cryoprecipitate makes them more effective in terms of their duration and mode of action when compared to factor FXIII concentrates.

In the event when the coagulopathy is secondary to anticoagulants, it is ideal first to use specific anticoagulation reversing agents and it is also necessary to consult a haematologist. [Table 8](#T8){ref-type="table"} highlights the specific reversal agents of various anticoagulants.^[@B17]^

###### 

Anticoagulant and the reversal agents

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Anticoagulant*                                       *Evaluation test*                         *Half-life (hours)*   *Reversible*   *Reversal agent(s)*\                                          *Reversal agent*\
                                                                                                                                       *Consult hematologist*                                        *Half-life*
  ----------------------------------------------------- ----------------------------------------- --------------------- -------------- ------------------------------------------------------------- -----------------------------------
  *Antithrombin III activator (FII and FX inhibitor)*                                                                                                                                                

  IV Heparin                                            aPTT                                      1.5                   Yes            Protamine (1mg/100 units heparin)                             7--8 minutes

  *Vitamin K inhibitor*                                                                                                                                                                              

  Warfarin                                              PT/INR                                    40                    Yes            Vitamin K 10 mg\                                              2 hours\
                                                                                                                                       Prothrombin complex concentrate\                              4--12 hours\
                                                                                                                                       20--50 units/kg\                                              2.3 hours\
                                                                                                                                       rFVIIa 90 µg/kg\                                              4--12 hours
                                                                                                                                       FFP                                                           

  *Factor X inhibitor*                                                                                                                                                                               

  LMWH Enoxaparin                                       Anti-FXa                                  7                     Partial        *Protamine*\                                                  7--8 minutes\
                                                                                                                                       *If received \<2 hours (60--80%)*\                            2.3 hours
                                                                                                                                       1mg protamine/1mg enoxaparin\                                 
                                                                                                                                       *If received \>8 hours before:*\                              
                                                                                                                                       0.5 mg protamine/1 mg enoxaparin\                             
                                                                                                                                       *If received \>12 hours* before: Nil\                         
                                                                                                                                       rFVIIa (70--90 mg/kg) in severe bleeds                        

  LMWH Dalteparin                                       Anti-FXa                                  3-5                   Partial        *Protamine*\                                                  7--8 minutes\
                                                                                                                                       *If received \<2 hours:* (60%)\                               2.3 hours
                                                                                                                                       1 mg protamine/1 mg dalteparin\                               
                                                                                                                                       rFVIIa (70--90 mg/kg) in severe bleeds                        

  *Direct FXa inhibitors*                                                                                                                                                                            

  Apixaban                                              Anti-FXa                                  8--15                 No             Andexxa (rXa, inactivated-zhzo)\                              1 hour\
                                                                                                                                       \<8 hours:400 mg--800 mg at 30 mg/minute; \>8 hours 400 mg\   4--60 hours
                                                                                                                                       Prothrombin complex concentrate\                              
                                                                                                                                       25--50 units/kg                                               

  Rivaroxaban                                           Anti-FXa                                  7--11                 No             Andexxa (rXa, inactivated-zhzo)\                              1 hour\
                                                                                                                                       \<8 hours:400 mg--800 mg at 30 mg/minute; \>8 hours 400 mg\   4--60 hours\
                                                                                                                                       Prothrombin complex concentrate\                              2.3 hours
                                                                                                                                       25--50 units/kg\                                              
                                                                                                                                       rFVIIa 90 mg/kg                                               

  *Direct FIIa inhibitors*                                                                                                                                                                           

  Dabigatran                                            Limited value except TT, TEG, anti-FIIa   12--17                No             Idarucizumab (if TT is prolonged)\                            Biphasic: 45 minutes, 4--8 hours\
                                                                                                                                       5 mg bolus or infusion over 5--10 minutes\                    4--12 hours
                                                                                                                                       Prothrombin complex concentrate\                              
                                                                                                                                       50 units/kg                                                   

  Argatroban                                            Limited value except TEG anti-FIIa        0.75                  No             rFVIIa 90 µg/kg                                               2.3 hours

  *Tissue plasminogen activator*                                                                                                                                                                     

  Alteplase                                             D-dimer                                   0.5--0.75             Yes            Tranexamic acid 10 mg/kg                                      2 hours
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SUMMARY
=======

Coagulopathy is common in intensive care and can be multifactorial. It is crucial to find the underlying cause and understand the limitations of various tests to assess them. Early hematology referral is vital. FFPs remain the broad-spectrum therapy to correct coagulopathy.
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